Advertisement

Kshivets_SPB_WSCTS2022Eso.pdf

thoracic/abdominal/general surgeon & surgical oncologist at Siauliai Public Hospital
Dec. 21, 2022
Advertisement

More Related Content

Advertisement

Kshivets_SPB_WSCTS2022Eso.pdf

  1. Esophageal Cancer: Precise Prediction KSHIVETS OLEG, MD, PHD SURGERY DEPARTMENT, ROSHAL HOSPITAL, ROSHAL, MOSCOW, RUSSIA
  2. ABSTRACT OBJECTIVE: 5-survival (5YS) and life span after radical surgery for esophageal cancer (EC) patients (ECP) (T1- 4N0-2M0) was analyzed. METHODS: We analyzed data of 556 consecutive ECP (age=56.5±8.9 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2022 (m=415, f=141; esophagogastrectomies (EG) Garlock=287, EG Lewis=269, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=167; adenocarcinoma=318, squamous=228, mix=10; T1=129, T2=115, T3=184, T4=128; N0=281, N1=70, N2=205; G1=157, G2=141, G3=258; early EC=110, invasive=446; only surgery=424, adjuvant chemoimmunoradiotherapy-AT=132: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence. RESULTS: Overall life span (LS) was 1877±2221.6 days and cumulative 5-year survival (5YS) reached 52%, 10 years – 45%, 20 years – 33.4%, 30 years – 27%. 186 ECP lived more than 5 years (LS=4283.3±2412.6 days), 99 ECP – more than 10 years (LS=5883±2296.6 days). 227 ECP died because of EC (LS=631.8±323.4 days). AT significantly improved 5YS (60.3% vs. 42%) (P=0.0029 by log-rank test). Cox modeling displayed that 5YS of ECP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, prothrombin index, hemorrhage time, residual nitrogen, protein (P=0.000-0.021). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and P PT early-invasive EC (rank=1); healthy cells/CC (2), erythrocytes/CC (3), PT N0—N12 (4) thrombocytes/CC (5); segmented neutrophils/CC (6), stick neutrophils/CC (7), lymphocytes/CC (8), monocytes/CC (9); leucocytes/CC (10); eosinophils/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5-year survival of ECP after radical procedures significantly depended on: 1) PT “early-invasive cancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) EC characteristics; 9) tumor localization; 10) anthropometric data; 11) surgery type. Optimal diagnosis and treatment strategies for EC are: 1) screening and early detection of EC; 2) availability of experienced thoracoabdominal surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for ECP with unfavorable prognosis.
  3. Data:  Males…………………………………………………...415  Females………..……………………………...............141  Age=56.5±8.9 years  Tumor Size=6±3.5 cm  Only Surgery.……………………………………........424  Adjuvant Chemoimmunoradiotherapy  (5FU+thymalin/taktivin, 5-6 cycles+ Radiotherapy  45-50Gy)………………………..................................132
  4. Radical Procedures:  Esophagogastrectomies Lewis (R0)…………………269  Esophagogastrectomies Garlock (R0)………...........287  Combined Esophagogastrectomies with Resection  of Pancreas, Liver, Trachea, Lung, Aorta, Vena  Cava Superior, Colon Transversum, Diaphragm, Pericardium, Splenectomy (R0)……………...............167  2-Field Lymphadenectomy…………………………….366  3-Field Lymphadenectomy.………………………….…190
  5. Staging:  T1……129 N0..….281 G1…………157  T2……115 N1….....70 G2…………141  T3……184 N2…...205 G3…………258  T4……128 M0…..556  Adenocarcinoma…………………………….318  Squamos Cell Carcinoma…………………..228  Mix………………….....…………………...........10  Early Cancer……………………………...…...110  Invasive Cancer…………………………..…..446
  6. Survival Rate:  Alive……………………………………….....292 (52.5%)  5-Year Survivors…………..……………….186 (33.5%)  10-Year Survivors…………………………...99 (17.8%)  Losses………………………………………..227 (40.8%)  General Life Span=1877±2221.6 days  For 5-Year Survivors=4283.3±2412.6 days  For 10-Year Survivors=5883±2296.6 days  For Losses=631.8±323.4 days  Cumulative 5-Year Survival……………………..52%  Cumulative 10-Year Survival…………………....45%  Cumulative 20-Year Survival…………………....33.4%
  7. General Esophageal Cancer Patients Survival after Complete Esophagogastrectomies (Kaplan-Meier) (n=556): Survival Function 5YS=52%; 10YS=45%; 20YS=33.4%. Complete Censored -5 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomy 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving
  8. Results of Univariate Analysis of Phase Transition Early—Invasive Cancer in Prediction of Esophageal Cancer Patients Survival (n=556): Cumulative Proportion Surviving (Kaplan-Meier) 5YS of Early ECP=100%; 5YS of Invasive ECP=39.2%; P=0.0000 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomy 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Invasive ECP=446 Early ECP=110
  9. Results of Univariate Analysis of Phase Transition N0—N1-2 in Prediction of Esophageal Cancer Patients Survival (n=556): Cumulative Proportion Surviving (Kaplan-Meier) 5YS of ECP with N0=73.4%; 5YS of ECP with N12=29%; P=0.0000 byLog-Rank Test. Complete Censored 0 5 10 15 20 25 30 35 40 Years after Esophagogastrectomy 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving ECP with N12 ECP with N0
  10. Results of Univariate Analysis of Adjuvant Chemoimmunoradiotherapy in Prediction of Esophageal Cancer Patients Survival (n=556): Cumulative Proportion Surviving (Kaplan-Meier) 5YS of ECP after Adjuvant Chemoimmunoradiotherapy=68.4%; 5YS of ECP after Surgery along=48.6%; P=0.0005 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 30 Years after Esophagogastrectomy 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving ECP after Adjuvant Chemoimmunoradiotherapy ECP after Surgery along
  11. Results of Univariate Analysis of Localization (Upper/3 vs. Others) in Prediction of Esophageal Cancer Patients Survival (n=556): Cumulative Proportion Surviving (Kaplan-Meier) 5YS of ECP in Upper/3=65%; 5YS of Others ECP=49.6%; P=0.00297 by Log-Rank Test. Complete Censored 0 5 10 15 20 25 Years after Esophagogastrectomy 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Cumulative Proportion Surviving Others ECP with Upper/3
  12. Results of Cox Regression Modeling in Prediction of Esophageal Cancer Patients Survival after Complete Esophagogastrectomies (n=556): Cox Regression, n=556 Parameter Estimate Standard Error Chi-square P value Hazard Ratio Hemorrhage Time 0.00149 0.000397 14.05790 0.000177 1.00149 Residual Nitrogen 0.04793 0.010884 19.39363 0.000011 1.04910 Protein 0.02047 0.008585 5.68498 0.017111 1.02068 Prothrombin Index 0.02498 0.006343 15.50974 0.000082 1.02529 T1-4 0.42183 0.085559 24.30742 0.000001 1.52475 Phase Transition N0--N12 0.61686 0.160454 14.78006 0.000121 1.85311 Age 0.02866 0.007712 13.80670 0.000203 1.02907 Histology -0.28849 0.124708 5.35127 0.020707 0.74940 G1-3 0.42478 0.088723 22.92255 0.000002 1.52926 Adjuvant Treatment -0.86575 0.189974 20.76792 0.000005 0.42074 Segmented Neutrophils/Cancer Cells 3.68226 1.601024 5.28972 0.021452 39.73610 Localization -0.55622 0.190510 8.52432 0.003504 0.57337 Monocytes/Cancer Cells 3.96567 1.658738 5.71581 0.016813 52.75566 Lymphocytes/Cancer Cells 3.54668 1.621453 4.78447 0.028717 34.69776 Stick Neutrophils/Cancer Cells 3.97424 1.661423 5.72201 0.016754 53.20991 Leucocytes/Cancer Cells -3.74966 1.608956 5.43121 0.019780 0.02353 EEosinophils/Cancer Cells 3.89197 1.687090 5.32184 0.021060 49.00719
  13. Results of Neural Networks Computing in Prediction of Esophageal Cancer Patients Survival after Complete esophagogastrectomies (n=413): Corect Classification Rate=100% Error=0.000 Area under ROC Curve=1.000 Factors (n=413) Rank Sensitivity Phase Transition Early---Invasive Cancer 1 24671 Healthy Cells/Cancer Cells Erythrocytes/Cancer Cells Phase Transition N0—N12 Thrombocytes/Cancer Cells Segmented Neutrophils/Cancer Cells Stick Neutrophils/Cancer Cells Lymphocytes/Cancer Cells Monocytes/Cancer Cells Leucocytes/Cancer Cells Eosinophils/Cancer Cells 2 3 4 5 6 7 8 9 10 11 23071 18425 18188 12766 7861 7164 6424 6229 5643 4982
  14. Results of Bootstrap Simulation in Prediction of esophageal Cancer Patients Survival after esophagogastrectomies (n=413): Significant Factors (Number of Samples=3333) Rank Kendal Tau-A P Tumor Size 1 -0.308 0.000 Healthy Cells/Cancer Cells 2 0.305 0.000 T1-4 3 -0.299 0.000 Erythrocytes/Cancer Cells 4 0.299 0.000 Leucocytes/Cancer Cells 5 0.290 0.000 Thrombocytes/Cancer Cells 6 0.285 0.000 Lymphocytes/Cancer Cells 7 0.281 0.000 Residual Nitrogen 8 -0.275 0.000 Segmented Neutrophils/Cancer Cells 9 0.273 0.000 Phase Transition N0---N12 10 -0.239 0.000 Hemorrhage Time 11 -0.228 0.000 Monocytes/Cancer Cells 12 0.227 0.000 Phase Transition Early---Invasive Cancer 13 -0.222 0.000 Esophageal/Cardioesophageal Cancer 14 -0.191 0.000 Operation Type 15 -0.187 0.000 Eosinophils/Cancer Cells 16 0.173 0.000 Stick Neutrophils/Cancer Cells 17 0.144 0.001 G1-3 18 -0.140 0.001 Tumor Growth 19 -0.113 0.01 Erythrocytes 20 0.100 0.01 Combined Procedure 21 0.095 0.01 Weight 22 0.092 0.01 Localization 23 0.069 0.05
  15. Results of Kohonen Self-Organizing Neural Networks Computing in Prediction of Esophageal Cancer Patients Survival after Complete Esophagogastrectomies (n=413):
  16. Esophageal Cancer Dynamics:
  17. Prognostic SEPATH-Model of Esophageal Cancer Patients Survival after Complete Esophagogastrectomies (n=413):
  18. 5-year survival of ECP after radical procedures significantly depended on: 1) PT “Early-Invasive Ccancer”; 2) PT N0--N12; 3) Cell Ratio Factors; 4) Blood Cell Circuit; 5) Biochemical Factors; 6) Hemostasis System; 7) Adjuvant Treatment; 8) EC Characteristics; 9) Tumor Localization; 10) Anthropometric Data; 11) Surgery Type. CONCLUSION:
  19. Address: Oleg Kshivets, M.D.,Ph.D. Consultant Thoracic, Abdominal, General Surgeon & Surgical Oncologist  e-mail: okshivets@yahoo.com  skype: okshivets  http: //www.ctsnet.org/home/okshivets
Advertisement